GLP-1s, the Menstrual Cycle, and Reproductive Hormones: What the Evidence Shows

The short version

Women starting a GLP-1 often notice their cycles change — sometimes becoming more regular, sometimes with a stretch of irregularity as weight drops. The best-supported explanation is indirect: weight loss and improved insulin signaling shift the hormonal environment that governs ovulation, and the menstrual cycle follows¹. In women with polycystic ovary syndrome, adding a GLP-1 has been associated with more regular cycles, more ovulation, and higher pregnancy rates in trials¹. But two things deserve equal billing: the trial evidence outside PCOS is close to non-existent, and the same fertility signal that helps some women is exactly why contraception and pregnancy timing are not optional details¹.

The mechanism: weight and insulin, then the ovary

The clearest lever GLP-1s pull is weight. International guidance on PCOS is built around weight reduction because losing weight can improve ovulation, insulin resistance, and metabolic markers² — and GLP-1 drugs are among the most effective weight-loss tools available, producing roughly 15% average loss with semaglutide in its pivotal trial⁴. As weight and insulin resistance fall, circulating androgens tend to decline and the hypothalamic-pituitary-ovarian axis that times ovulation can normalize, which is the proposed route by which cycles become more regular¹.

There may also be a more direct component. Reviews note that GLP-1 receptors are expressed in reproductive tissues, and that these drugs may exert anti-inflammatory, antifibrotic, and androgen-lowering effects — with at least one agent reported to improve follicular development and endometrial receptivity in study settings¹. That direct pathway is biologically plausible but far less established than the weight-mediated one.

What the trials actually show

Most of the human evidence comes from PCOS, where weight, insulin, and reproduction are already entangled. A 2026 narrative review of the fertility literature — a search of PubMed, SciELO and LILACS yielding 47 relevant articles published between 2014 and 2025 — found consistent metabolic benefits and emerging reproductive signals: increased menstrual regularity, ovulation, and pregnancy, particularly when a GLP-1 was combined with metformin¹.

Those are the strongest numbers in this field, and they are single-trial numbers inside a narrative review — the weakest review design, chosen here because it is the only one that has gathered the reproductive literature in one place.

The caution is that pooled evidence is much weaker on reproductive endpoints than on weight. A 2026 systematic review and meta-analysis of GLP-1 receptor agonists in PCOS confirmed the weight-loss signal but rated the certainty low, and found the data insufficient to draw a conclusion on glucose, insulin, hirsutism, or menstrual regularity³. When a formal meta-analysis and a narrative review disagree this sharply, the meta-analysis is the one to believe about how much is actually known. Our semaglutide and GLP-1s for PCOS evidence guide goes deeper on that population.

Outside PCOS: one signal, and it is not from a trial

It would be easy to write that nobody has looked at cycles in women without PCOS. Somebody has — just not with a trial. A 2026 study in Obstetrics and Gynecology ran disproportionality and Bayesian analyses on the FDA Adverse Event Reporting System through March 2026, restricted to female patients aged 12–55. Semaglutide showed the broadest signal profile, with disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea and anovulatory cycles. Tirzepatide generated signals for intermenstrual bleeding and menstrual clots. Liraglutide produced none⁵.

What that is worth: a spontaneous-reporting database has no denominator. Disproportionality means an event was reported more often than expected relative to other drugs in the same system — it cannot tell you how common the event is, cannot separate the drug from the rapid weight loss it causes, and is vulnerable to reporting bias in a heavily publicized drug class. The authors' own framing is that the findings "suggest pleiotropic effects on menstrual physiology and may support inclusion of menstrual health in counseling"⁵. Counseling, not causation. But it does mean that if your bleeding pattern changes on a GLP-1, you are not the first and it is worth telling your clinician.

The part that isn't optional: contraception and pregnancy

Improving ovulation means improving the chance of conceiving — sometimes unexpectedly, in women who assumed they couldn't. GLP-1 drugs are not used in pregnancy given limited human data and fetal risks seen in animal studies, and semaglutide and tirzepatide require roughly an 8–10 week washout before attempting conception¹.

The pill interaction is more specific than it is usually described. Zepbound's prescribing information, read on DailyMed (label version dated 6 May 2026), states that tirzepatide may reduce the efficacy of oral hormonal contraceptives through delayed gastric emptying, that the delay is largest after the first dose and diminishes over time, and instructs patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation⁶. Hormonal contraceptives not taken by mouth are not affected⁶. That is a defined window, not a vague caution — and it repeats at every dose increase, which is the part people miss.

What good care looks like

Because this sits at the intersection of metabolism and reproduction, the provider matters. Look for a clinician who asks about your cycle history and pregnancy plans up front, discusses contraception before the first dose, and frames the medication as one lever alongside the lifestyle foundation the guidelines emphasize².

Where this sits on the evidence scale

That weight loss shifts reproductive hormones: strong, and old. It is the mechanism the entire PCOS guideline is built on, independent of any drug².

That GLP-1s improve cycles and ovulation in PCOS: low. The encouraging figures come from individual small trials collected in a narrative review; the systematic review that pooled the randomized data called the menstrual-regularity evidence insufficient to conclude anything³.

That GLP-1s do anything to cycles in women without PCOS: no trial evidence. What exists is a pharmacovigilance signal — hypothesis-generating, denominator-free, and unable to separate the drug from the weight loss.

The tirzepatide–contraceptive interaction: labeled and quantified. That one you can act on, and the four-week window resets with every dose increase.

What would change the picture: a randomized trial with menstrual and ovulatory endpoints pre-specified, enrolling women who do not have PCOS. Nobody has run one.